These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27837664)

  • 21. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.
    Vorobyeva A; Westerlund K; Mitran B; Altai M; Rinne S; Sörensen J; Orlova A; Tolmachev V; Karlström AE
    Sci Rep; 2018 Jun; 8(1):9643. PubMed ID: 29942011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
    Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
    J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
    Wållberg H; Grafström J; Cheng Q; Lu L; Martinsson Ahlzén HS; Samén E; Thorell JO; Johansson K; Dunås F; Olofsson MH; Stone-Elander S; Arnér ES; Ståhl S
    J Nucl Med; 2012 Sep; 53(9):1446-53. PubMed ID: 22872744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with
    Tolmachev V; Yim CB; Rajander J; Perols A; Karlström AE; Haaparanta-Solin M; Grönroos TJ; Solin O; Orlova A
    Contrast Media Mol Imaging; 2017; 2017():8565802. PubMed ID: 29097939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Evaluation of
    Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.
    Tolmachev V; Velikyan I; Sandström M; Orlova A
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1356-67. PubMed ID: 20130858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.
    Rosik D; Thibblin A; Antoni G; Honarvar H; Strand J; Selvaraju RK; Altai M; Orlova A; Eriksson Karlström A; Tolmachev V
    Bioconjug Chem; 2014 Jan; 25(1):82-92. PubMed ID: 24344772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
    Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
    Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
    J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
    Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
    J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
    Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.